Real‐World Treatment With Faricimab Improves Anatomical Biomarkers in Patients With Diabetic Macular Edema

Introduction Diabetic macular edema (DME) is a leading cause of vision loss in people with diabetes. Treatments include the use of anti–vascular endothelial growth factor (VEGF) agents such as faricimab. The aims of the study were to evaluate the effectiveness and safety of treatment with faricimab and its effect on anatomical biomarkers in a real‐world setting in Spain. Methods A retrospective observational study of data from clinical records of patients with DME treated with intravitreal injections of faricimab at Hospital Universitario Virgen Macarena (Spain) was carried out. Best‐corrected visual acuity (BCVA), central macular thickness (CMT), and optical coherence tomography biomarkers (intraretinal fluid [IRF] and subretinal fluid [SRF], hyperreflective foci [HRF], disorganized retinal inner layer [DRIL], and epiretinal membrane [ERM]) were evaluated at baseline and after treatment with faricimab. Results Sixty‐three eyes of 44 patients were included. Most eyes (88.9%) had been previously treated. After treatment with faricimab, the patients showed significant improvement in BCVA from a mean Early Treatment of Diabetic Retinopathy Study (ETDRS) score of 53.75–57.48 ( p = 0.023) and a significant reduction in CMT from a mean of 337.71–297.18 μm ( p < 0.001). The percentage of patients with IRF and HRF significantly reduced after faricimab treatment from 95.2% to 71.0% ( p < 0.001) and 61.3% to 46.8% ( p < 0.05), respectively. The correlation analysis showed that the number of faricimab injections received was positively and significantly associated with a difference in BCVA ( p < 0.05). No adverse events were reported. Conclusions Treatment with intravitreal faricimab injection significantly improved visual acuity and anatomical biomarkers in patients with DME, with no adverse events in routine clinical practice, highlighting its potential as an effective and safe therapeutic option.